LANDSCAPE: Phase II study with lapatinib and capecitabine in
patients with brain metastases from
HER2-positive MBC before whole brain radiotherapy
Bachelot et al. Lancet Oncol 2013;14:64.
•
NSS improvement: 14/24 = 58% (95% CI: 37, 78)
•
Extra CNS ORR: 44%
•
Median TTP: 5.5 months
•
Median time to WBRT: 8.3 months
•
OS 17m
CNS-OR: 29/44 = 65.9% (95% CI: 50.1, 79.5)
CNS volumetric change
N (n=44), (%)
≥80% reduction
9
(20)
50–<80% reduction
20
(45)
20–<50% reduction
6
(14)
>0–<20% reduction
2
(5)
Progression*
7
(16)
*Two patients had progression
outside of the CNS
